A patient whose tumor presented with an FGFR2-MGEA5 fusion has demonstrated preliminary evidence of anti-tumor activity manifest as stable disease accompanied by CA19-9 reduction and tumor necrosis to ponatinib, a pan-FGFR inhibitor (in vitro FGFR1 IC50≈24 nM, FGFR2 IC50≈8 nM, FGFR3 IC50≈8 nM and FGFR4 IC50≈34 nM). Here, FGFR1 is linked to neoplasm.